Recombinant human adenovirus-p53 improves the outcome of mid-late stage pancreatic cancer via arterial infusion.

导出 OA

翻译打印收藏纠错

作者： Jinggang,Mo ^[1] ; Meihua,Lin ^[2] ; Bin,He ^[3] ; Kai,Tan ^[4] ; Chong,Jin ^[5] ; Hao,Jiang ^[2] ; Xuefeng,Pan ^[2] ; Weidong,Lin ^[2]

作者单位： Department of Hepatobiliary Surgery, First Clinical College, Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China. ^[1] Department of Hepatobiliary Surgery, Taizhou Central Hospital, Taizhou, Zhejiang 318000, P.R. China. ^[2] Research Center of Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China. ^[3] Department of Gastrointestinal Surgery, Taizhou Central Hospital, Taizhou, Zhejiang 325000, P.R. China. ^[4] Department of Radiology, Taizhou Central Hospital, Taizhou, Zhejiang 325000, P.R. China. ^[5]

关键词 computed tomography intervention therapy pancreatic cancer recombinant human adenovirus-p53

DOI 10.3892/ol.2017.7058

PMID 29181104

发布时间 2022-03-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交